• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry.在接受经皮冠状动脉介入治疗的东亚患者中高出血风险和临床结局:PENDULUM 注册研究。
EuroIntervention. 2021 Feb 19;16(14):1154-1162. doi: 10.4244/EIJ-D-20-00345.
2
Validation of the academic research consortium high bleeding risk definition in Thai PCI registry.验证学术研究联盟高出血风险定义在泰国 PCI 注册研究中的应用。
Int J Cardiol. 2023 Oct 1;388:131167. doi: 10.1016/j.ijcard.2023.131167. Epub 2023 Jul 8.
3
Validation of the Domestic High Bleeding Risk Criteria for Japanese Patients with Acute Myocardial Infarction.验证日本急性心肌梗死患者国内高出血风险标准。
J Atheroscler Thromb. 2023 Mar 1;30(3):299-309. doi: 10.5551/jat.63576. Epub 2022 May 25.
4
Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention.学术研究联盟高出血风险标准在经皮冠状动脉介入治疗所有患者登记中的应用。
Circ Cardiovasc Interv. 2019 Nov;12(11):e008307. doi: 10.1161/CIRCINTERVENTIONS.119.008307. Epub 2019 Nov 11.
5
Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention - From the CREDO-Kyoto Registry Cohort-3.改良的日本患者高出血风险标准在经皮冠状动脉介入治疗所有患者登记研究中的应用 - 来自 CREDO-Kyoto 登记研究队列-3。
Circ J. 2021 May 25;85(6):769-781. doi: 10.1253/circj.CJ-20-0836. Epub 2020 Dec 8.
6
Association between the number of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome.急性冠状动脉综合征患者的学术研究联盟高出血风险(ARC-HBR)标准数量与临床结局的关系。
J Cardiol. 2023 Jun;81(6):553-563. doi: 10.1016/j.jjcc.2023.01.003. Epub 2023 Jan 20.
7
Applicability of the Academic Research Consortium for High Bleeding Risk in acute coronary syndrome undergoing percutaneous coronary intervention.急性冠状动脉综合征行经皮冠状动脉介入治疗中高出血风险的学术研究协作适用性。
Rev Esp Cardiol (Engl Ed). 2022 May;75(5):375-383. doi: 10.1016/j.rec.2021.03.006. Epub 2021 Apr 14.
8
Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores.验证学术研究协作组高出血风险(ARC-HBR)标准在经皮冠状动脉介入治疗患者中的应用,并与当代出血风险评分进行比较。
EuroIntervention. 2020 Aug 28;16(5):371-379. doi: 10.4244/EIJ-D-20-00052.
9
Validation of the Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria in patients undergoing peripheral endovascular interventions.验证学术研究联合会高出血风险(ARC-HBR)标准在外周血管内介入治疗患者中的应用。
EuroIntervention. 2023 Apr 3;18(16):e1368-e1377. doi: 10.4244/EIJ-D-22-00475.
10
Comparison and Validation of Long-Term Bleeding Events for Academic Bleeding Risk (ARC-HBR) Criteria and Contemporary Risk Scores for Percutaneous Coronary Intervention With a Second-Generation Drug Eluting Stent.比较和验证第二代药物洗脱支架经皮冠状动脉介入治疗的学术出血风险(ARC-HBR)标准和当代风险评分的长期出血事件。
Circ J. 2022 Aug 25;86(9):1379-1387. doi: 10.1253/circj.CJ-21-0901. Epub 2022 Apr 9.

引用本文的文献

1
Development and validation of a machine learning-based explainable predictive model for long-term net adverse clinical events in patients with high bleeding risk undergoing percutaneous coronary intervention: results from a prospective cohort study.基于机器学习的可解释预测模型的开发与验证,用于预测高出血风险经皮冠状动脉介入治疗患者的长期净不良临床事件:一项前瞻性队列研究的结果
Int J Surg. 2025 Sep 1;111(9):6082-6092. doi: 10.1097/JS9.0000000000002744. Epub 2025 Jun 23.
2
Successful or Uncomplicated Use of Drug-Coated Balloon Versus Drug-Eluting Stent Strategies for De Novo Culprit Lesions in Acute Coronary Syndromes: Insights from a Nationwide Registry in Japan.药物涂层球囊与药物洗脱支架策略在急性冠状动脉综合征初发罪犯病变中的成功或无并发症使用:来自日本全国性注册研究的见解
J Am Heart Assoc. 2025 Jun 3;14(11):e038071. doi: 10.1161/JAHA.124.038071. Epub 2025 May 29.
3
Post-discharge major bleeding/all-cause death in acute coronary syndrome: academic research consortium criteria versus Japan-specific criteria.急性冠状动脉综合征出院后大出血/全因死亡:学术研究联盟标准与日本特定标准对比
BMC Cardiovasc Disord. 2025 May 15;25(1):370. doi: 10.1186/s12872-025-04834-1.
4
Percutaneous Coronary Intervention: Sex Differences May Not Matter After All.经皮冠状动脉介入治疗:性别差异或许终究并无影响。
JACC Asia. 2025 Apr;5(4):552-553. doi: 10.1016/j.jacasi.2024.11.016.
5
Sex Differences in Outcomes After Contemporary Percutaneous Coronary Intervention: Insights From the PENDULUM Registry.当代经皮冠状动脉介入治疗后结局的性别差异:来自PENDULUM注册研究的见解
JACC Asia. 2025 Apr;5(4):543-551. doi: 10.1016/j.jacasi.2024.09.017.
6
Development and Validation of a Nomogram for Predicting Long-Term Net Adverse Clinical Events in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention.用于预测接受经皮冠状动脉介入治疗的高出血风险患者长期净不良临床事件的列线图的开发与验证
Rev Cardiovasc Med. 2025 Jan 17;26(1):25352. doi: 10.31083/RCM25352. eCollection 2025 Jan.
7
Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy.冠心病介入治疗患者个性化抗血小板治疗的进展分析
Rev Cardiovasc Med. 2024 Dec 25;25(12):462. doi: 10.31083/j.rcm2512462. eCollection 2024 Dec.
8
Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity.冠状动脉支架置入术后长期服用阿司匹林与氯吡格雷的出血风险及手术复杂性比较
JAMA Cardiol. 2025 May 1;10(5):427-436. doi: 10.1001/jamacardio.2024.4030.
9
One-Month Dual Antiplatelet Therapy in High Bleeding Risk Asian Patients Undergoing Percutaneous Coronary Intervention - Onyx ONE Clear 2-Year Results.亚洲高出血风险经皮冠状动脉介入治疗患者的1个月双联抗血小板治疗——玛瑙ONE清除2年结果
Circ Rep. 2024 Jul 6;6(8):333-340. doi: 10.1253/circrep.CR-24-0037. eCollection 2024 Aug 9.
10
Predictive Value of HAS-BLED and HEMORR2HAGES Bleeding Risk Scores After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后 HAS-BLED 和 HEMORR2HAGES 出血风险评分的预测价值。
Tex Heart Inst J. 2024 Jul 10;51(2). doi: 10.14503/THIJ-23-8267.

本文引用的文献

1
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients.当代经皮冠状动脉介入治疗患者中学术研究联盟高出血风险定义的验证。
J Am Coll Cardiol. 2020 Jun 2;75(21):2711-2722. doi: 10.1016/j.jacc.2020.03.070.
2
Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry.东亚患者经皮冠状动脉介入治疗后血小板反应性与缺血和出血事件的关系:PENDULUM 登记研究的 1 年结果。
J Am Heart Assoc. 2020 May 18;9(10):e015439. doi: 10.1161/JAHA.119.015439. Epub 2020 May 12.
3
Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores.验证学术研究协作组高出血风险(ARC-HBR)标准在经皮冠状动脉介入治疗患者中的应用,并与当代出血风险评分进行比较。
EuroIntervention. 2020 Aug 28;16(5):371-379. doi: 10.4244/EIJ-D-20-00052.
4
Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention.学术研究联盟高出血风险标准在经皮冠状动脉介入治疗所有患者登记中的应用。
Circ Cardiovasc Interv. 2019 Nov;12(11):e008307. doi: 10.1161/CIRCINTERVENTIONS.119.008307. Epub 2019 Nov 11.
5
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.定义行经皮冠状动脉介入治疗患者的高出血风险。
Circulation. 2019 Jul 16;140(3):240-261. doi: 10.1161/CIRCULATIONAHA.119.040167. Epub 2019 May 22.
6
Post-interventional adverse event risk by vascular access site among patients with acute coronary syndrome in Japan: observational analysis with a national registry J-PCI database.日本急性冠状动脉综合征患者血管入路部位的介入后不良事件风险:基于全国注册J-PCI数据库的观察性分析
Cardiovasc Interv Ther. 2019 Oct;34(4):297-304. doi: 10.1007/s12928-019-00582-0. Epub 2019 Mar 7.
7
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).2017年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的冠状动脉疾病双联抗血小板治疗重点更新:欧洲心脏病学会(ESC)和欧洲心胸外科学会(EACTS)冠状动脉疾病双联抗血小板治疗特别工作组。
Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.
8
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2016美国心脏病学会/美国心脏协会关于冠状动脉疾病患者双联抗血小板治疗持续时间的指南聚焦更新:美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115. doi: 10.1016/j.jacc.2016.03.513. Epub 2016 Mar 29.
9
Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.专家共识文件:世界心脏联合会专家共识声明:抗血小板治疗在东亚 ACS 或 PCI 患者中的应用。
Nat Rev Cardiol. 2014 Oct;11(10):597-606. doi: 10.1038/nrcardio.2014.104. Epub 2014 Aug 26.
10
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.在日本急性冠脉综合征患者中,调整剂量的普拉格雷与氯吡格雷相比的疗效和安全性:PRASFIT-ACS研究
Circ J. 2014;78(7):1684-92. doi: 10.1253/circj.cj-13-1482. Epub 2014 Apr 22.

在接受经皮冠状动脉介入治疗的东亚患者中高出血风险和临床结局:PENDULUM 注册研究。

High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry.

机构信息

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.

出版信息

EuroIntervention. 2021 Feb 19;16(14):1154-1162. doi: 10.4244/EIJ-D-20-00345.

DOI:10.4244/EIJ-D-20-00345
PMID:32624464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9725071/
Abstract

AIMS

We aimed to evaluate the validity of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria for East Asian patients undergoing contemporary percutaneous coronary intervention (PCI) from the PENDULUM registry.

METHODS AND RESULTS

This post hoc analysis included 6,267 Japanese patients undergoing PCI between December 2015 and June 2017 enrolled in PENDULUM. The primary endpoint was the incidence of major bleeding at 12 months post index PCI. In total, 3,185 (50.8%) and 3,082 (49.2%) patients were stratified to the ARC-HBR and non-ARC-HBR groups, respectively, and almost all patients had overlapping criteria. Incidence of major bleeding was 4.2% versus 1.4% in the ARC-HBR group versus the non-ARC-HBR group (hazard ratio 3.00 [95% confidence interval: 2.11-4.27]; p<0.001). As the number of overlapping ARC-HBR criteria increased, the incidence of major bleeding also increased. In contrast, the incidence of major bleeding was 4.2% for one major criterion, 2.1% for two minor criteria. Multivariate analysis suggested that severe CKD, anticoagulant use, acute coronary syndrome, low body weight and heart failure were independent predictors of major bleeding.

CONCLUSIONS

Half of the Japanese patients who underwent PCI in the PENDULUM registry met the ARC-HBR criteria, and many patients had overlapping criteria. ARC-HBR criteria are applicable to Japanese patients undergoing contemporary PCI.

摘要

目的

我们旨在评估学术研究联盟高出血风险(ARC-HBR)标准在接受当代经皮冠状动脉介入治疗(PCI)的东亚患者中的有效性,该研究来自 PENDULUM 注册研究。

方法和结果

本事后分析纳入了 2015 年 12 月至 2017 年 6 月期间接受 PCI 的 6267 例日本患者,这些患者均来自 PENDULUM 注册研究。主要终点是索引性 PCI 后 12 个月时的主要出血发生率。总共,3185(50.8%)和 3082(49.2%)例患者分别被分到 ARC-HBR 和非 ARC-HBR 组,且几乎所有患者都有重叠的标准。主要出血发生率在 ARC-HBR 组和非 ARC-HBR 组分别为 4.2%和 1.4%(风险比 3.00 [95%置信区间:2.11-4.27];p<0.001)。随着 ARC-HBR 标准重叠数量的增加,主要出血的发生率也随之增加。相比之下,1 个主要标准的主要出血发生率为 4.2%,2 个次要标准的主要出血发生率为 2.1%。多变量分析提示严重 CKD、抗凝剂使用、急性冠状动脉综合征、低体重和心力衰竭是主要出血的独立预测因素。

结论

在 PENDULUM 注册研究中接受 PCI 的日本患者中有一半符合 ARC-HBR 标准,且许多患者有重叠标准。ARC-HBR 标准适用于接受当代 PCI 的日本患者。